Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;90(5):298-300.
doi: 10.1016/j.tube.2010.08.002. Epub 2010 Aug 23.

The abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis

Joel S Freundlich  1 , Mallikarjun Lalgondar, Jun-Rong Wei, Stephanie Swanson, Erik J Sorensen, Eric J Rubin, James C Sacchettini
Affiliations

The abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis

Joel S Freundlich et al. Tuberculosis (Edinb). 2010 Sep.

Abstract

The antimycobacterial efficacy of the abyssomicin C family of natural products, in addition to a key synthetic intermediate, has been investigated given their reported inhibition of Bacillus subtilis p-aminobenzoate biosynthesis. The naturally occurring (-)-abyssomicin C and its atropisomer were found to exhibit low micromolar growth inhibition against the relatively fast-growing and non-virulent Mycobacterium smegmatis and the vaccine strain Mycobacterium bovis BCG, while their antipodes were slightly less active. (-)-abyssomicin C and its atropisomer were particularly efficacious against Mycobacterium tuberculosis H37Rv, exhibiting MIC values of 3.6 and 7.2 μM, respectively. More specifically, (-)-abyssomicin C was bactericidal. This complex natural product and its analogs, thus, hold promise as chemical tools in the study of M. tuberculosis metabolism.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Chemical structures of the studied abyssomicin C family.
See this image and copyright information in PMC

References

    1. World Health Organization. Global tuberculosis control report. 2009.
    1. Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol. 2008;6:41–52. - PubMed
    1. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis. 2009;9:19–30. - PubMed
    1. Andries K, Verhasselt P, Guillemont J, Gohlmann HWH, Neefs J-M, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–7. - PubMed
    1. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405:962–6. - PubMed

Publication types

MeSH terms

LinkOut - more resources